Lixte Biotechnology Holdings, Inc. Share Price & Technical Analysis
LIXT · $5.74 (-2.38%)
Healthcare / Biotechnology
$5.74
-2.38%
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-1…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
74% return in May, 1% avg return in past 3 year May month.
78% return in 2026, 72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | -22% | 15% | 17% | 74% | – | – | – | – | – | – | – | 78% |
| 25 | 25% | -43% | -8% | 8% | -8% | -25% | 300% | 10% | 19% | -14% | 0% | -7% | 257% |
| 24 | -12% | 24% | 26% | -15% | -21% | 0% | -8% | -18% | 0% | 5% | 5% | -9% | -24% |
| 23 | 65% | 15% | -2% | -32% | 30% | -12% | -40% | -26% | 0% | 4% | -12% | -8% | -18% |
| 22 | 62% | -27% | -10% | -2% | -35% | -1% | 4% | 4% | -21% | -17% | 45% | -35% | -33% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Strong
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$57.97M
P/E ratio
—
52W high
$6.26
52W low
$0.64
Volume
15,726
Beta
1.05
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Lixte Biotechnology Holdings, Inc. share price today?
- Lixte Biotechnology Holdings, Inc. (LIXT) last traded around $5.74 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LIXT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LIXT. Download the app for real-time alerts.
- How can I analyze Lixte Biotechnology Holdings, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.